Apex Biotechnology Corp. (1733)
TWSE
30.15
-0.10 (-0.33%)
Closed
Oct 5, 2026
Day's Range
30.1530.80
52 wk Range
28.0038.70
Financial Statements - 1733 - Apex Biotechnology Corp.
Revenue
1.94B▲ 5.0%
Net Income
163.03M▲ 27.3%Net Margin 8.4%
EBITDA
268.53M▲ 21.2%
Free Cash Flow
140.85M▼ 52.9%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 1.94B | 1.85B | 1.67B | 2.24B | 2.13B | 2B |
| Cost of Goods | 1.40B | 1.33B | 1.14B | 1.66B | 1.56B | 1.55B |
| Gross Profit | 538.74M | 521.34M | 531.11M | 576.83M | 571.51M | 452.22M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 155.04M | 128.50M | 143.53M | 176.56M | 201.45M | 102.96M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 189.89M | 153.12M | 140.96M | 199.57M | 184.93M | 110.61M |
| Income Tax | 26.85M | 25.02M | 25.24M | 18.12M | -17.35M | 15.98M |
| Net Income | 163.03M | 128.10M | 115.71M | 181.45M | 202.28M | 94.62M |
| EPS Basic | 1.63 | 1.28 | 1.16 | 1.82 | 2.03 | 0.95 |
| EPS Diluted | 1.62 | 1.27 | 1.15 | 1.81 | 1.93 | 0.87 |
| Basic Shares Outstanding | 99.95M | 99.95M | 99.95M | 99.95M | 99.73M | 99.54M |
| Diluted Shares Outstanding | 99.95M | 99.95M | 99.95M | 99.95M | 99.73M | 99.54M |
| Ebit | 193.28M | 156.76M | 145.35M | 204.97M | 197.46M | 120.89M |
| Ebitda | 268.53M | 221.62M | 222.87M | 299.07M | 289.64M | 225.72M |
| Net Income Continuous Operations | 189.89M | 153.12M | 140.96M | 199.57M | 184.93M | 110.61M |
| Minority Interests | -146K | -106K | 69K | 334K | -65K | 166K |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
